TAK 580

Drug Profile

TAK 580

Alternative Names: AMG-2112819; BIIB-024; MLN-2480

Latest Information Update: 08 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biogen Idec; Sunesis Pharmaceuticals
  • Developer Sunesis Pharmaceuticals; Takeda Oncology
  • Class Antineoplastics
  • Mechanism of Action Raf kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • Phase I Malignant melanoma

Most Recent Events

  • 27 Oct 2017 Phase-II clinical trials in Solid tumours (PO)
  • 11 Oct 2017 TAK 580 is still in phase I trials for Solid tumours (Second-line therapy or greater) in USA and United Kingdom (NCT01425008)
  • 08 Sep 2017 Efficacy, safety and pharmacokinetics data from a phase I trial in Malignant melanoma and Solid tumours presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top